|
Price: $1.1100
$-0.01 
-0.893%
|
| Day's High:
| $1.16
| Week Perf:
| -11.9 %
|
| Day's Low: |
$ 1.10 |
30 Day Perf: |
-1.77 % |
| Volume (M): |
3,388 |
52 Wk High: |
$ 4.80 |
| Volume (M$): |
$ 3,761 |
52 Wk Avg: |
$2.17 |
| Open: |
$1.15 |
52 Wk Low: |
$1.01 |
|
|
| Market Capitalization (Millions $) |
263 |
| Shares
Outstanding (Millions) |
237 |
| Employees |
74 |
| Revenues (TTM) (Millions $) |
5 |
| Net Income (TTM) (Millions $) |
-100 |
| Cash Flow (TTM) (Millions $) |
289 |
| Capital Exp. (TTM) (Millions $) |
56 |
Gevo Inc
We are a renewable chemicals and next generation biofuels company. We have developed
proprietary technology that uses a combination of synthetic biology, metabolic
engineering, chemistry and chemical engineering to focus primarily on the production
of renewable isobutanol as well as related products from renewable feedstocks.
Isobutanol is a four-carbon alcohol that can be sold directly for use as a specialty
chemical in the production of solvents, paints and coatings or as a value-added
gasoline blendstock. Isobutanol can also be converted into butenes using dehydration
chemistry deployed in the refining and petrochemicals industries today. The convertibility
of isobutanol into butenes is important because butenes are primary hydrocarbon
building blocks used in the production of hydrocarbon fuels, including isooctane,
isooctene and alcohol-to-jet-fuel (“ATJ”), as well as lubricants,
polyester, rubber, plastics, fibers and other polymers. We believe that the products
derived from isobutanol have potential applications in substantially all of the
global hydrocarbon fuels markets and in approximately 40% of the global petrochemicals
markets.
Company Address: 345 Inverness Drive South Englewood 80112 CO
Company Phone Number: 858-8358 Stock Exchange / Ticker: NASDAQ GEVO
| GEVO is expected to report next financial results on August 07, 2023. |
|
|
|
|
Customers Net Income grew by |
GEVO's Customers Net Profit Margin grew to |
23.35 % |
13.47 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Rex American Resources Corporation
As a journalist covering financial results, I have analyzed the first quarter of 2023 earnings season for Rex American Resources Corporation. The company has achieved break-even of $0.00 per share, which is the same as the previous year. However, it is a significant improvement from the previous reporting period where it had earnings of $0.46 per share.
In terms of revenue, the company has shown growth of 9.518% to $212.71 million from $194.23 million in the corresponding reporting period a year earlier. Moreover, there has been a sequential growth of 6.268% from $200.17 million. This indicates that Rex American Resources Corporation has been successful in driving revenue growth, which is a positive sign for investors.
|
|
Csw Industrials Inc
Investors in the stock market are in for exciting news as CSW Industrials Inc releases its financial report for the period ending March 31, 2023. The chemical manufacturing company experienced impressive growth as profit per share soared by 38.71% to $1.75 per share, followed by a revenue boost of 12.918% to $195.69 million compared to the previous year. This financial milestone shows that CSW Industrials Inc is a company on the rise, with earnings per share soaring by 73.11% from $1.01 per share, while revenue advanced by 14.373% from $171.09 million.
CSW Industrials Inc also reported earnings of $27.122 million in the fiscal period closing March 31, 2023, representing a 35.75% increase from net earnings of $19.979 million reported in the fiscal period closing March 31, 2022, a year ago. There was a significant improvement in its profit margins, with net margin rising to 13.86% in the said period, and operating margin edging up to 20.32%. Operating earnings improved by 28.83% to $39.764 million.
|
|
Originclear Inc
It's been an exciting time in the stock market lately, with some fantastic news coming from Originclear Inc. The latest financial report shows that for the fiscal span closing March 31, 2023, the company reached a break-even of $0.00 per share, which is a significant improvement from the previous year's negative $0.01 per share, and even a slight improvement from the $0.02 per share in the previous quarter.
But that's not all - Originclear Inc also saw an impressive 62.579% rise in revenue, totaling $2.01 million, compared to just $1.23 million a year ago. And while it's worth noting that there was a 23.081% drop in sequential revenue from $2.61 million, there's no doubt that Originclear Inc is on an upward trajectory.
|
|
Asp Isotopes Inc
As a journalist, I have been following the financial results of the ASPI and it appears that stockholders were not expecting any significant changes in the business during the January to March quarter of 2023. However, investors are keeping a close eye on the company's operating loss which came in at $-3.724824 million during the same period.
It is worth noting that in the fiscal first quarter of 2023, Asp Isotopes Inc reported a net shortfall of $-3.615 million as opposed to a break-even in the same quarter of the previous year. This indicates that the company has experienced a significant decline in its financial performance over the past year, which is cause for concern among investors.
|
|
Artemis Therapeutics Inc
The Chemical Manufacturing company recently announced its revenue for the most recent fiscal period, which amounted to $0.173 million. This news is significant for the company as it showcases the financial health of the company and provides insights into its recent performance.
However, it is important to note that another company, Artemis Therapeutics Inc, did not report a positive financial outcome for the same reporting season. Instead of recording a zero gain, the company showed a net deficit of $-0.249 million. This news suggests that Artemis Therapeutics Inc is experiencing financial difficulties that are affecting its bottom lineInvestors and analysts are likely to closely monitor Artemis Therapeutics Inc in the coming months to see if the company can bounce back from its losses and improve its financial outlook. The company is expected to report its next financial earnings on May 22, 2023, which will provide updates on its progress.
While both companies operate in different industries and have distinct business models, the news of their respective financial outcomes serves as a reminder of the importance of financial reporting. Companies that publicly disclose their earnings enable investors and stakeholders to evaluate their financial performance and make informed decisions about whether to invest in the company.
In conclusion, the news of Chemical Manufacturing company's revenue and Artemis Therapeutics Inc's net deficit offer important insights into the financial health of these companies and can help investors and stakeholders make informed decisions. As we continue to navigate the uncertain economic climate, monitoring financial reports remains a crucial task for all market participants.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.41 $ |
| Revenues (TTM) |
0.02 $
|
| Cash Flow (TTM) |
1.22 $ |
| Cash |
1.59 $
|
| Book Value |
2.5 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.41 $
|
| Revenues (TTM) |
0.02 $ |
| Cash Flow (TTM) |
1.22 $ |
| Cash |
1.59 $
|
| Book Value |
2.5 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.04% 